VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
1-Year Return
31.42%
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
64.25%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Kura Oncology
KURA
$713M
| $112K | 0.03% |
+16,942
| New | +$112K |
|
402
Tourmaline Bio
TRML
$687M
| $111K | 0.03% |
+7,289
| New | +$111K |
|
403
Spyre Therapeutics
SYRE
$1.03B
| $111K | 0.03% |
+6,861
| New | +$111K |
|
404
Nuvation Bio
NUVB
$1.33B
| $110K | 0.03% |
+62,421
| New | +$110K |
|
405
Oric Pharmaceuticals
ORIC
$1.06B
| $109K | 0.03% |
+19,473
| New | +$109K |
|
406
Capricor Therapeutics
CAPR
$308M
| $109K | 0.03% |
+11,448
| New | +$109K |
|
407
Prime Medicine
PRME
$663M
| $109K | 0.03% |
+54,535
| New | +$109K |
|
408
Cartesian Therapeutics
RNAC
$277M
| $108K | 0.03% |
+8,160
| New | +$108K |
|
409
Kymera Therapeutics
KYMR
$3.11B
| $106K | 0.03% |
+3,891
| New | +$106K |
|
|
CMPS
410
Compass Pathways
CMPS
$493M
| $106K | 0.03% |
+37,225
| New | +$106K |
|
411
IDEAYA Biosciences
IDYA
$2.38B
| $104K | 0.03% |
+6,368
| New | +$104K |
|
412
Cullinan Oncology
CGEM
$413M
| $102K | 0.03% |
+13,455
| New | +$102K |
|
413
Immunovant
IMVT
$2.99B
| $102K | 0.03% |
+5,953
| New | +$102K |
|
414
Taysha Gene Therapies
TSHA
$917M
| $101K | 0.03% |
+72,957
| New | +$101K |
|
415
Perspective Therapeutics
CATX
$257M
| $101K | 0.03% |
+47,307
| New | +$101K |
|
416
Tyra Biosciences
TYRA
$674M
| $101K | 0.03% |
+10,818
| New | +$101K |
|
417
Immatics
IMTX
$761M
| $99.9K | 0.03% |
+22,153
| New | +$99.9K |
|
418
Arcturus Therapeutics
ARCT
$485M
| $99K | 0.03% |
+9,353
| New | +$99K |
|
419
Crinetics Pharmaceuticals
CRNX
$3.35B
| $99K | 0.03% |
+2,953
| New | +$99K |
|
|
MREO
420
Mereo BioPharma
MREO
$282M
| $99K | 0.03% |
+44,007
| New | +$99K |
|
421
Biohaven
BHVN
$1.68B
| $98.2K | 0.03% |
+4,083
| New | +$98.2K |
|
422
Monte Rosa Therapeutics
GLUE
$305M
| $97.8K | 0.03% |
+21,073
| New | +$97.8K |
|
423
Wave Life Sciences
WVE
$1.32B
| $95.7K | 0.03% |
+11,850
| New | +$95.7K |
|
424
Altimmune
ALT
$334M
| $95.6K | 0.03% |
+19,116
| New | +$95.6K |
|
425
Denali Therapeutics
DNLI
$2.26B
| $95K | 0.03% |
+6,991
| New | +$95K |
|